A 24-month, Prospective, Non-interventional Study to Describe the Long Term, Real-Life Use of BOTOX for the symptomatic treatment of Adults with Chronic Migraine, Measuring Healthcare Resource Utilization, and Patient Reported Outcomes Observed in Practice.

Trial Profile

A 24-month, Prospective, Non-interventional Study to Describe the Long Term, Real-Life Use of BOTOX for the symptomatic treatment of Adults with Chronic Migraine, Measuring Healthcare Resource Utilization, and Patient Reported Outcomes Observed in Practice.

Completed
Phase of Trial: Phase IV

Latest Information Update: 27 Apr 2018

At a glance

  • Drugs Botulinum-Toxin-A (Primary)
  • Indications Migraine
  • Focus Therapeutic Use
  • Acronyms REPOSE
  • Sponsors Allergan
  • Most Recent Events

    • 27 Apr 2018 Results presented at the 70th Annual Meeting of the American Academy of Neurology
    • 29 Nov 2017 According to an Allergan media release, data from the study will be presented at the 11th European Headache Federation (EHF) Congress 2017.
    • 10 Sep 2017 Results assessing long term use of Onabotulinumtoxin A (BOTOX) as prescribed by the physician for headache prophylaxis in adults with chronic migraine, were presented at the 2017 International Headache Society.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top